Patents by Inventor A. Edward Osawa
A. Edward Osawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8512729Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: GrantFiled: October 31, 2012Date of Patent: August 20, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian-Wallis
-
Patent number: 8383141Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.Type: GrantFiled: July 21, 2008Date of Patent: February 26, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich
-
Patent number: 8357378Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: GrantFiled: May 24, 2011Date of Patent: January 22, 2013Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa
-
Patent number: 8303981Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: GrantFiled: July 1, 2011Date of Patent: November 6, 2012Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian-Wallis
-
Publication number: 20120207813Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.Type: ApplicationFiled: April 26, 2012Publication date: August 16, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Woonza M. RHEE, Cary J. REICH, A. Edward OSAWA, Felix VEGA
-
Publication number: 20120134980Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: ApplicationFiled: July 1, 2011Publication date: May 31, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa, Zhen Qian-Wallis
-
Publication number: 20120128653Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) mixing said first component and said second component under conditions effective to form a wet paste while essentially preventing degradation of the second component by said first component in a final container or transferring said wet paste into a final container, d) freezing and lyophilizing said paste in said container thereby obtaining a dry and stable hemostatic composition comprising said first and said second component in lyophilized form, and e) finishing said dry and stable hemostatic composition in said final container to a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.Type: ApplicationFiled: June 1, 2011Publication date: May 24, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Andreas Goessl, Atsushi Edward Osawa, Cary J. Reich
-
Publication number: 20120121532Abstract: Described is a process for making a dry and stable hemostatic composition, said process comprising a) providing a first component comprising a dry preparation of a coagulation inducing agent, b) providing a second component comprising a dry preparation of a biocompatible polymer suitable for use in hemostasis, c) providing said first component and said second component in a combined form in a final container, c1) either by filling said first component and said second component into said final container so as to obtain a dry mixture in said final container, c2) or by providing said first component or said second component in said final container and adding said second component or said first component so as to obtain a combination of said first component with said second component in said final container, d) finishing the final container to. a storable pharmaceutical device containing said first component and said second component in a combined form as a dry and stable hemostatic composition.Type: ApplicationFiled: June 1, 2011Publication date: May 17, 2012Applicants: Baxter Healthcare S.A., Baxter International Inc.Inventors: Andreas Goessl, Atsushi Edward Osawa, Cary J. Reich
-
Patent number: 8092820Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.Type: GrantFiled: May 19, 2009Date of Patent: January 10, 2012Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich
-
Publication number: 20110223231Abstract: Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.Type: ApplicationFiled: May 24, 2011Publication date: September 15, 2011Applicants: Baxter International Inc., Baxter Healthcare S.A.Inventors: Donald G. Wallace, Cary J. Reich, Narinder S. Shargill, Felix Vega, A. Edward Osawa
-
Publication number: 20110202026Abstract: The present invention provides a hemostatic composite sponge comprising a porous matrix of a biomaterial and a material enhancing the adherence of said sponge to the applied tissue stably associated with at least one surface of said sponge, a method of producing these sponges and their use in hemostasis.Type: ApplicationFiled: December 16, 2010Publication date: August 18, 2011Applicants: Baxter International Inc., Baxter Healthcare S.A.Inventors: Hans Christian Hedrich, Joris Hoefinghoff, Woonza M. Rhee, Atsushi Edward Osawa
-
Patent number: 7871637Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.Type: GrantFiled: September 21, 2007Date of Patent: January 18, 2011Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich, Donald G. Wallace, Narinder S. Shargill, Felix Vega
-
Publication number: 20090227779Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.Type: ApplicationFiled: May 19, 2009Publication date: September 10, 2009Applicants: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich
-
Patent number: 7547446Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.Type: GrantFiled: June 21, 2007Date of Patent: June 16, 2009Assignees: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich
-
Publication number: 20080286376Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.Type: ApplicationFiled: July 21, 2008Publication date: November 20, 2008Applicant: Fusion Medical Technologies, Inc.Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich
-
Patent number: 7435425Abstract: Dry cross-linked gelatin compositions are prepared that rapidly re-hydrate to produce gelatin hydrogels suitable as hemostatic sealants. Gelatin is cross-linked in the presence of certain re-hydration aids, such as polyethylene glycol, polyvinylprovidone, and dextran, in order to produce a dry cross-linked gelatin powder. The use of the re-hydration aids has been found to substantially increase the re-hydration rate in the presence of an aqueous re-hydration medium, typically thrombin-containing saline.Type: GrantFiled: July 17, 2001Date of Patent: October 14, 2008Assignees: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Zhen Qian, A. Edward Osawa, Cary J. Reich
-
Publication number: 20080187591Abstract: Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross-linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.Type: ApplicationFiled: August 1, 2007Publication date: August 7, 2008Applicants: Baxter International, Inc., Baxter Healthcare S.A.Inventors: Woonza M. Rhee, Cary J. Reich, A. Edward Osawa, Felix Vega
-
Patent number: 7320962Abstract: Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the cross-linked polymer will be present in a particulate or fragmented form. The materials are particularly suitable for hemostasis and drug delivery.Type: GrantFiled: January 20, 2004Date of Patent: January 22, 2008Assignees: Baxter International Inc., Baxter Healthcare S.A.Inventors: Cary J. Reich, A. Edward Osawa, Helen Tran
-
Publication number: 20040214770Abstract: Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the cross-linked polymer will be present in a particulate or fragmented form. The materials are particularly suitable for hemostasis and drug delivery.Type: ApplicationFiled: January 20, 2004Publication date: October 28, 2004Applicant: Fusion Medical Technologies, Inc.Inventors: Cary J. Reich, A. Edward Osawa, Helen Tran
-
Patent number: 6706690Abstract: Dried hemoactive materials comprise both a cross-linked biologically compatible polymer and a non-cross-linked biologically compatible polymer. The cross-linked polymer is selected to form a hydrogel when exposed to blood. The non-cross-linked polymer is chosen to solubilize relatively rapidly when exposed to blood. The non-cross-linked polymer serves as a binder for holding the materials in desired geometries, such as sheets, pellets, plugs, or the like. Usually, the cross-linked polymer will be present in a particulate or fragmented form. The materials are particularly suitable for hemostasis and drug delivery.Type: GrantFiled: June 10, 1999Date of Patent: March 16, 2004Assignee: Baxter Healthcare CorporationInventors: Cary J. Reich, A. Edward Osawa, Helen Tran